Name | Brivaracetam |
CAS number | 357337-00-9 |
Description | Brivaracetam, (αR,4R)- is a third-generation antiepileptic drug and anticonvulsant that is typically used in combination with other antiepileptic medications for partial onset seizures. Brivaracetam, (αR,4R)- has a high-affinity ligand for synaptic vesicle protein 2A. Brivaracetam, (αR,4R)- acts by binding to a synaptic vesicle glycoprotein, SV2A, and reducing the release of neurotransmitters. Brivaracetam, (αR,4R)- is primarily metabolized by hydrolysis, via amidase enzymes, to an inactive metabolite. |
Related CAS | / |
Synonym | Brivaracetam, (αR,4R)- ;(αR,4R)-Brivaracetam; |
Appearance | Solid powder |
Quality Standard | USP, EP, BP, CP |
Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
Storage Condition | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Shelf Life | >2 years if stored properly |
Sample package | Aluminium foil bag |
Commercial package | Aluminium Tin, Fiber drum |
Origin | China |
Brivaracetam More Info
Brivaracetam is a second - generation antiepileptic drug (AED) developed as a successor to levetiracetam, with a similar mechanism of action but higher affinity for its target.
1. Mechanism of Action
Brivaracetam exerts its antiepileptic effect primarily by selectively binding to the synaptic vesicle protein 2A (SV2A) in the brain. This binding modulates the release of neurotransmitters, especially reducing the excessive release of excitatory neurotransmitters (such as glutamate) that are associated with seizure activity. Compared to levetiracetam, it has a 10 - fold higher affinity for SV2A, which contributes to its potent efficacy at lower doses.
2. Indications
It is mainly approved for the adjunctive treatment of partial - onset seizures in adult and pediatric patients (aged 4 years and older) with epilepsy. Partial - onset seizures, also known as focal seizures, start in a specific area of the brain and may or may not spread to the entire brain.
3. Key Characteristics
(1) Pharmacokinetics
Rapid absorption: Oral administration results in fast and nearly complete absorption, with peak plasma concentrations reached within 1 - 2 hours.
Minimal metabolism: A large portion (about 20 - 30%) of the drug is excreted unchanged in the urine. The remaining part is metabolized mainly by hydrolysis, without involving the cytochrome P450 enzyme system, which means a low risk of drug - drug interactions.
Short half - life: The elimination half - life is approximately 7 - 8 hours in adults, allowing for twice - daily dosing.
(2) Efficacy and Tolerability
It shows good efficacy in reducing the frequency of partial - onset seizures, even in patients who have not responded well to other antiepileptic drugs.
Common adverse effects are generally mild to moderate, including dizziness, somnolence, headache, nausea, and fatigue. These side effects often diminish over time as the body adjusts to the drug.
4. Dosage and Administration
The dosage is individualized based on the patient's age, weight, and clinical response. For adults, the usual starting dose is 50 mg twice daily, which can be adjusted up to a maximum of 200 mg twice daily if needed.
It is available in oral formulations such as tablets, oral solution, and film - coated tablets, to meet the needs of different patients (e.g., those who have difficulty swallowing tablets).
5. Contraindications and Precautions
Contraindication: Hypersensitivity to brivaracetam or any of its excipients.
Precautions:
Patients with renal impairment may require dosage adjustment, as the drug is mainly excreted via the kidneys.
Abrupt discontinuation of the drug should be avoided, as it may increase the risk of seizure exacerbation. The dose should be tapered gradually over a period of at least 1 week.
Caution is advised when driving or operating machinery, as the drug may cause dizziness and somnolence.
